Pittalis S, Ferarro F, Puro V
Dipartimento di Epidemiologia e Ricerca Preclinica, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani, Roma, Italy.
Infez Med. 2011 Dec;19(4):224-34.
A novel type of carbapenemase, New Delhi metallo beta-lactamase 1 (NDM 1), was first identified in 2008 in two Enterobacteriacea isolates, both recovered from a Swedish patient transferred from India. The emergence of NDM 1 is now reported from all continents, often in patients with a history of travel or hospitalization in the Indian subcontinent. The NDM 1 producing Gram-negative bacteria are mainly Enterobacteriaceae, which can cause colonization or fatal infections, with worrying antimicrobial susceptibility profiles: some isolates have developed resistance to practically all available antibiotics. Is the NDM-1 the super-bug? Are we in the post-antibiotic era? This review is a summary of currently available knowledge of NDM-1 that draws attention to future antimicrobial resistance scenarios.
2008年，在从印度转诊至瑞典的一名患者身上分离出的两株肠杆菌科细菌中首次发现了一种新型碳青霉烯酶——新德里金属β-内酰胺酶1（NDM-1）。目前各大洲均有NDM-1出现的报道，常发生于有印度次大陆旅行史或住院史的患者中。产NDM-1的革兰氏阴性菌主要是肠杆菌科细菌，可引起定植或致命感染，其抗菌药敏谱令人担忧：一些分离株对几乎所有可用抗生素均产生了耐药性。NDM-1是超级细菌吗？我们是否处于后抗生素时代？这篇综述总结了目前关于NDM-1的已有知识，提请关注未来的抗菌药物耐药情况。
